Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CorMedix Inc stock logo
CRMD
CorMedix
$7.95
-1.3%
$7.02
$6.13
$17.43
$623.14M1.462.02 million shs293,524 shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$10.12
+0.3%
$7.29
$5.37
$17.58
$625.39M1.771.15 million shs466,703 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.46
$1.88
$0.64
$2.73
$489.16M2.37.77 million shs8.27 million shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$0.81
+2.4%
$0.73
$0.36
$2.35
$175.77M2.774.07 million shs2.65 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CorMedix Inc stock logo
CRMD
CorMedix
+4.14%+7.62%+13.70%+9.52%-27.87%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+4.23%+35.27%+47.05%+21.01%+56.67%
Ocugen, Inc. stock logo
OCGN
Ocugen
-2.35%-13.39%-17.80%+9.40%+103.44%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
+4.76%+19.67%+19.73%+5.36%+69.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CorMedix Inc stock logo
CRMD
CorMedix
$7.95
-1.3%
$7.02
$6.13
$17.43
$623.14M1.462.02 million shs293,524 shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$10.12
+0.3%
$7.29
$5.37
$17.58
$625.39M1.771.15 million shs466,703 shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.46
$1.88
$0.64
$2.73
$489.16M2.37.77 million shs8.27 million shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$0.81
+2.4%
$0.73
$0.36
$2.35
$175.77M2.774.07 million shs2.65 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CorMedix Inc stock logo
CRMD
CorMedix
+4.14%+7.62%+13.70%+9.52%-27.87%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+4.23%+35.27%+47.05%+21.01%+56.67%
Ocugen, Inc. stock logo
OCGN
Ocugen
-2.35%-13.39%-17.80%+9.40%+103.44%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
+4.76%+19.67%+19.73%+5.36%+69.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CorMedix Inc stock logo
CRMD
CorMedix
2.63
Moderate Buy$15.0088.80% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.67
Reduce$8.50-15.97% Downside
Ocugen, Inc. stock logo
OCGN
Ocugen
2.60
Moderate Buy$9.75570.10% Upside
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
2.86
Moderate Buy$4.00394.44% Upside

Current Analyst Ratings Breakdown

Latest TNYA, CRMD, OCGN, and DNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/28/2026
CorMedix Inc stock logo
CRMD
CorMedix
Reiterated RatingOutperform$13.00 ➝ $14.00
4/28/2026
CorMedix Inc stock logo
CRMD
CorMedix
Reiterated RatingMarket Outperform$19.00
4/28/2026
CorMedix Inc stock logo
CRMD
CorMedix
Boost Price TargetOutperform$13.00 ➝ $14.00
4/27/2026
CorMedix Inc stock logo
CRMD
CorMedix
Boost Price TargetBuy$14.00 ➝ $15.00
4/27/2026
CorMedix Inc stock logo
CRMD
CorMedix
Reiterated RatingBuy$14.00
4/20/2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
Reiterated RatingSell (D-)
3/25/2026
Ocugen, Inc. stock logo
OCGN
Ocugen
Reiterated RatingBuy$7.00
3/25/2026
Ocugen, Inc. stock logo
OCGN
Ocugen
Boost Price TargetBuy$7.00 ➝ $10.00
3/17/2026
Ocugen, Inc. stock logo
OCGN
Ocugen
Initiated CoverageBuy$12.00
3/12/2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Reiterated RatingOutperform$2.00
3/12/2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Reiterated RatingOutperform
(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CorMedix Inc stock logo
CRMD
CorMedix
$311.71M2.00$2.10 per share3.78$5.14 per share1.55
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$170.15M3.68N/AN/A$8.74 per share1.16
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.41M111.69N/AN/A($0.04) per share-36.38
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/A$0.57 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CorMedix Inc stock logo
CRMD
CorMedix
$163.05M$2.003.9756.75N/A52.31%52.30%29.46%5/14/2026 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$312.76M-$5.65N/AN/AN/A-183.81%-52.82%-25.45%5/7/2026 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$67.85M-$0.23N/AN/AN/A-1,192.18%-2,626.38%-138.99%N/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$90.60M-$0.62N/AN/AN/AN/A-85.20%-69.96%5/13/2026 (Estimated)

Latest TNYA, CRMD, OCGN, and DNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
CorMedix Inc stock logo
CRMD
CorMedix
$0.35N/AN/AN/A$104.96 millionN/A
5/13/2026Q1 2026
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$0.09-$0.09N/A-$0.09$7.50 million$0.23 million
5/7/2026Q1 2026
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$1.2112N/AN/AN/A$42.93 millionN/A
5/5/2026Q1 2026
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.05-$0.06-$0.01-$0.06$0.42 million$1.53 million
3/11/2026Q4 2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$0.12-$0.12N/A-$0.12N/AN/A
3/5/2026Q4 2025
CorMedix Inc stock logo
CRMD
CorMedix
$0.86$0.16-$0.70$0.16$127.02 million$128.62 million
3/4/2026Q4 2025
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.06-$0.06N/A-$0.06$0.86 million($0.19) million
2/26/2026Q4 2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$1.80-$1.42+$0.38-$1.42$37.57 million$33.40 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CorMedix Inc stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CorMedix Inc stock logo
CRMD
CorMedix
0.36
2.11
1.94
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
4.92
4.92
Ocugen, Inc. stock logo
OCGN
Ocugen
8.04
1.06
1.06
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/A
6.84
6.84

Institutional Ownership

CompanyInstitutional Ownership
CorMedix Inc stock logo
CRMD
CorMedix
34.18%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
90.54%

Insider Ownership

CompanyInsider Ownership
CorMedix Inc stock logo
CRMD
CorMedix
3.10%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
9.72%
Ocugen, Inc. stock logo
OCGN
Ocugen
4.42%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
48.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
CorMedix Inc stock logo
CRMD
CorMedix
3078.44 million76.01 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64061.92 million55.91 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80338.52 million323.56 millionOptionable
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
110217.00 million111.43 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CorMedix stock logo

CorMedix NASDAQ:CRMD

$7.94 -0.11 (-1.30%)
As of 12:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$10.12 +0.04 (+0.35%)
As of 12:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$1.46 0.00 (0.00%)
As of 12:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Tenaya Therapeutics stock logo

Tenaya Therapeutics NASDAQ:TNYA

$0.81 +0.02 (+2.38%)
As of 12:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.